Teresa Whalen talks about CytoAgents and the treatment of Cytokine Storm

30Nov

Teresa Whalen talks about CytoAgents and the treatment of Cytokine Storm

Portfolio News
Teresa Whalen is the CEO of CytoAgents, a startup focused on the development of solutions to combat persistent and potentially deadly strains of Influenza, COVID19, and other viruses. Teresa’s career spans 20 years in the healthcare industry, including health technology executive, life sciences investor, and clinical pharmacist. She has brought multiple successful life-changing healthcare products to market. Read more >>

Share this post

Related Posts

09Feb

Easier-To-Produce Room Temperature Covid Shot Shows Promise In Early Clinical Trials

A protein-based Covid-19 vaccine by Akston Biosciences that can be stored at room temperature and efficiently manufactured using existing technology... read more
12Nov

Feast or famine? Natural foods companies grapple with COVID realities

While everyone needs to eat — pandemic or no pandemic — and grocery stores have mostly thrived through the COVID-19... read more
01Nov

Siamab Therapeutics Presents New PreClinical Safety Data

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data demonstrating the... read more
17Nov

Electronic glasses help blind woman see 20/20

“Oh! It's working,” Belskis said, as she turned on her brand new electronic glasses made by eSight. In Belskis' case, she... read more
21Apr

NEW STUDY: ONLY ONE QUARTER OF U.S. ADULTS WILL HAVE CABLE TV IN A FEW YEARS

Pixability, the provider of software and insights for video advertising on YouTube and other leading connected TV (CTV) platforms, today... read more
22Nov

Aircuity to Begin Installation at Virginia Commonwealth University

Aircuity, creator of measurably better environments, announces that it will begin installation at three laboratory research buildings at the Virginia... read more
11Dec

Acworth teens sees again with new eyewear

An Acworth teen is seeing clearly for the first time in 12 years. She lost most of her vision at... read more
16Sep

RevBio Receives Approval from the U.K.’s Regulatory Authority to Initiate a Clinical Trial for an Optimized Formulation of its Dental Bone Adhesive Biomaterial

RevBio, Inc., announced that it has received approval from the Medicines and Healthcare products Regulatory Agency in the United Kingdom... read more
16Feb

It all left in the blink of an eye

A new solution has been put forward to Michael-Gagne, now, through technology called eSight glasses — electronic glasses for the... read more
05Jan

eSight wants to help 50 million people living with vision loss see by 2020

Toronto-based eSight has launched a pledge to help the 50 million people worldwide living with vision loss and blindness by... read more